Generics BRIC (Brazil, Russia, India, China) Industry Guide 2015-2024


The BRIC Generics industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2015-19, and forecast to 2024). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Highlights

  • Brazil, Russian Federation, India and China (BRIC) are the emerging and fast growing countries within the generics industry and had a total market value of $101,698.1 million in 2019. Russia was the fastest growing country with a CAGR of 11.8% over the 2015-19 period.
  • Within the generics industry, China is the leading country among the BRIC nations with market revenues of $69,811.0 million in 2019. This was followed by India, Russia and Brazil with a value of $16,448.5, $9,127.7, and $6,310.9 million, respectively.
  • China is expected to lead the generics industry in the BRIC nations with a value of $89,577.3 million in 2024, followed by India, Russia, Brazil with expected values of $23,292.4, $11,252.0 and $8,175.3 million, respectively.


  • Save time carrying out entry-level research by identifying the size, growth, and leading players in the BRIC generics market
  • Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the BRIC generics market
  • Leading company profiles reveal details of key generics market players’ BRIC operations and financial performance
  • Add weight to presentations and pitches by understanding the future growth prospects of the BRIC generics market with five year forecasts by both value and volume
  • Compares data from Brazil, Russia, India, and China, alongside individual chapters on each country

Reasons To Buy

  • What was the size of the BRIC generics market by value in 2019?
  • What will be the size of the BRIC generics market in 2024?
  • What factors are affecting the strength of competition in the BRIC generics market?
  • How has the market performed over the last five years?
  • How large is the BRIC generics market in relation to its regional counterparts?